Cargando…

Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination

BACKGROUND: Maraviroc-containing combined antiretroviral therapy (MVC-cART) improved the response to the hepatitis B virus (HBV) vaccine in HIV-infected subjects younger than 50 years old. We aimed here to explore the effect of this antiretroviral therapy on different immunological parameters that c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrero-Fernández, Inés, Rosado-Sánchez, Isaac, Genebat, Miguel, Tarancón-Díez, Laura, Rodríguez-Méndez, María Mar, Pozo-Balado, María Mar, Lozano, Carmen, Ruiz-Mateos, Ezequiel, Leal, Manuel, Pacheco, Yolanda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116502/ https://www.ncbi.nlm.nih.gov/pubmed/30157873 http://dx.doi.org/10.1186/s12967-018-1617-1

Ejemplares similares

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Partial restoration of gut‐mucosal dysbiosis in late‐treated HIV‐infected subjects with CD4 T‐cell recovery
por: Olivas‐Martínez, Israel, et al.
Publicado: (2022)

Polyfunctional HIV-1 specific response by CD8+ T lymphocytes expressing high levels of CD300a
por: Vitallé, Joana, et al.
Publicado: (2020)

Longitudinal age differences in humoral responses to the COVID-19 vaccine in the elderly are lost after the third dose
por: Pozo-Balado, María del Mar, et al.
Publicado: (2022)

Altered Expression of CD300a Inhibitory Receptor on CD4+ T Cells From Human Immunodeficiency Virus-1-Infected Patients: Association With Disease Progression Markers
por: Vitallé, Joana, et al.
Publicado: (2018)

HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation
por: Rosado-Sánchez, Isaac, et al.
Publicado: (2018)

Dysregulation of iron metabolism modulators in virologically suppressed HIV-infected patients
por: Garrido-Rodríguez, Vanesa, et al.
Publicado: (2022)

Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance—Supercontrollers
por: Dominguez-Molina, Beatriz, et al.
Publicado: (2018)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Coronavirus Disease (COVID-19): A Perspective from Immunosenescence
por: Genebat, Miguel, et al.
Publicado: (2021)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Threshold Ferritin Concentrations Reflecting Early Iron Deficiency Based on Hepcidin and Soluble Transferrin Receptor Serum Levels in Patients with Absolute Iron Deficiency
por: Tarancon-Diez, Laura, et al.
Publicado: (2022)

Immunometabolism is a key factor for the persistent spontaneous elite control of HIV-1 infection
por: Tarancon-Diez, Laura, et al.
Publicado: (2019)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
por: Ilomuanya, Margaret O., et al.
Publicado: (2020)

The use of alpha 1 thymosin as an immunomodulator of the response against SARS-Cov2
por: Espinar-Buitrago, M. S., et al.
Publicado: (2023)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Persistent Exhausted T-Cell Immunity after Severe COVID-19: 6-Month Evaluation in a Prospective Observational Study
por: Vazquez-Alejo, Elena, et al.
Publicado: (2023)

Long-term Persistent Elite HIV-controllers: The Right Model of Functional Cure
por: Tarancon-Diez, Laura, et al.
Publicado: (2018)

Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients
por: Piconi, Stefania, et al.
Publicado: (2016)

Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home
por: Pozo-Balado, María del Mar, et al.
Publicado: (2023)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

Persistent HIV‐controllers are more prone to spontaneously clear HCV: a retrospective cohort study
por: Dominguez‐Molina, Beatriz, et al.
Publicado: (2020)

Immunological features beyond CD4/CD8 ratio values in older individuals
por: Garrido-Rodríguez, Vanesa, et al.
Publicado: (2021)

Immunologic impact of maraviroc in clinical practice of a university hospital
por: Paniagua, S Plata, et al.
Publicado: (2010)

Incidence of ischemic cardiovascular events in the maraviroc clinical development program
por: Portsmouth, S, et al.
Publicado: (2010)

Maraviroc: a review of its use in HIV infection and beyond
por: Woollard, Shawna M, et al.
Publicado: (2015)

Maraviroc-Mediated Lung Protection following Trauma-Hemorrhagic Shock
por: Liu, Fu-Chao, et al.
Publicado: (2016)

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C
por: Pujari, Sanjay, et al.
Publicado: (2018)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

HIV entry blocked by maraviroc can cause an overestimation of viral load
por: Sloan, RD, et al.
Publicado: (2010)

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient
por: Bregigeon, Sylvie, et al.
Publicado: (2010)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

Role of maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced
por: Cipriani, S, et al.
Publicado: (2012)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity
por: Legnani, L., et al.
Publicado: (2016)

Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control
por: Moyano, Ana, et al.
Publicado: (2022)

Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice
por: Potard, Valérie, et al.
Publicado: (2015)

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
por: López-Huertas, María Rosa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1hfpv6ir9hs4qogbpjq78m1tiu